Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity

Sidharth S. Bhardwaj, Naga Chalasani

Research output: Contribution to journalReview article

101 Scopus citations


The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.

Original languageEnglish (US)
Pages (from-to)597-613
Number of pages17
JournalClinics in Liver Disease
Issue number3
StatePublished - Aug 1 2007

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity'. Together they form a unique fingerprint.

  • Cite this